IL37 and psoriasis: Several case reports have described the clinical efficacy of IL-12/IL-23 inhibitors including ustekinumab, guselkumab, risankizumab, and risankizumab in COVID-19 patients with psoriasis.278–282 The reliability of case reports is relatively weak, which is why randomized, controlled, prospective clinical trials are so important.